Tranexamic%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520acid

# Tranexamic Acid ## Overview Tranexamic acid (TXA) is a synthetic lysine analog that acts as an antifibrinolytic agent. It competitively inhibits the activation of plasminogen to plasmin, thereby preventing the degradation of fibrin clots and stabilizing hemostasis. ## Primary Indications * **Trauma:** Reduction of mortality in patients with significant hemorrhage (CRASH-2 protocol). * **Surgery:** Reduction of perioperative blood loss in orthopedic, cardiac, and spinal surgeries. * **Obstetrics:** Treatment and prevention of postpartum hemorrhage. * **Menorrhagia:** Treatment of cyclic heavy menstrual bleeding. * **Epistaxis/Hemoptysis:** Often used topically or systemically for refractory cases. ## Adult Dosing * **Trauma (CRASH-2):** 1 g IV bolus over 10 minutes, followed by 1 g IV infusion over 8 hours. Administer as soon as possible, ideally within 3 hours of injury. * **Heavy Menstrual Bleeding:** 1,300 mg orally three times daily for up to 5 days during menses. * **Surgical Prophylaxis:** Varies widely by specialty; common ranges are 10–30 mg/kg IV bolus followed by variable infusions based on local protocol. ## Pediatric Dosing * **Trauma:** 15 mg/kg (up to 1 g) IV bolus, followed by 2 mg/kg/hour infusion for up to 8 hours. * **Cardiac/Surgical:** Dosing is highly variable; common loading doses range from 10–30 mg/kg depending on institutional cardiovascular surgery protocols. Consultation with specialized pediatric pharmacy or anesthesia protocols is required. ## Dose Adjustments * **Renal Impairment:** Requires dose reduction in patients with CrCl <50 mL/min. * CrCl 30–50 mL/min: 50% of standard dose or increased dosing interval. * CrCl <30 mL/min: Use caution; 25% of standard dose or profound interval extension. * **Hepatic Impairment:** No specific dosage adjustments established, but use with caution. ## Contraindications * Active intravascular clotting (e.g., DVT, PE, history of thromboembolism) unless the patient is anticoagulated. * Acquired defective color vision (prevents monitoring of optic nerve toxicity). * Subarachnoid hemorrhage (risk of cerebral ischemia/vasospasm). * Hypersensitivity to tranexamic acid. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain. * **Serious:** Thromboembolic events (PE, DVT, MI, stroke), seizures (particularly with high doses or rapid IV administration), and visual disturbances (e.g., blurred vision, central retinal artery occlusion). ## Key Drug Interactions * **Procoagulants/Estrogens:** Risk of thrombosis is cumulatively increased when combined with factor IX complex concentrates or estrogen-containing products. * **Thrombolytics:** Concurrent use with thrombolytic agents (e.g., alteplase) significantly negates the effect of both drugs; avoid combination. ## Monitoring * **Clinical:** Monitor for signs of new thrombi (leg swelling, chest pain, dyspnea). * **Neurological:** Monitor for seizures (especially in renal impairment). * **Ophthalmological:** Baseline and periodic eye exams recommended if long-term therapy is required; stop immediately if visual changes occur. * **Laboratory:** Renal function tests in patients requiring repeat or ongoing dosing. ## Clinical Pearls * **Administration:** Rapid IV injection can cause hypotension; always infuse over at least 10 minutes. * **The "3-Hour Rule":** In major trauma, the efficacy of TXA markedly decreases and potential harm/no benefit may occur if administered later than 3 hours post-injury. * **Topical Use:** TXA is increasingly used topically (e.g., in mouthwash for dental procedures or soaked gauze for epistaxis) to minimize systemic absorption. * **Protocol Dependency:** Always defer to institutional clinical guidelines for surgical and ICU dosing, as there is significant variation in "standard" practice protocols. *** **Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Prescribing practices, local protocols, and safety profiles can change. Always verify current prescribing information, package inserts, and hospital-specific guidelines before administration.